Developing intrathoracic sentinel lymph node mapping with near-infrared fluorescent imaging in non-small cell lung cancer

Denis M. Gilmore, MD, Onkar V. Khullar, MD, and Yolonda L. Colson, MD, PhD

With poor survival and high recurrence rates, early-stage lung cancer currently appears to be understaged or undertreated, or both. Although sentinel lymph node biopsy is standard for patients with breast cancer and melanoma, its success has been unreliable in non-small cell lung cancer. Sentinel lymph node biopsy might aid in the identification of lymph nodes at the greatest risk of metastasis and allow for more detailed analysis to select for patients who might benefit from adjuvant therapy. The early results in our recent clinical trial of patients with early-stage lung cancer have suggested that near-infrared imaging might offer a platform for reliable sentinel lymph node identification in these patients. (*J Thorac Cardiovasc Surg* 2012;144:S80-4)

Lung cancer continues to be the leading cause of cancer death in the United States. Because of the large number of patients presenting with advanced disease, the 5-year survival for all patient with lung cancer has improved only slightly from 11.5% in 1975 to 16.0% in 2003.¹ Furthermore, for patients with stage I disease thought to have undergone curative resection, the recurrence rates have remained high, at nearly 40%, with overall 5-year survival of 52.2%.¹ When the local lymph nodes are involved, the 5-year survival decreases by nearly one half, making nodal involvement the most important prognostic factor. The high incidence of recurrent disease among patient with stage I lung cancer suggests that these patients are currently understaged or undertreated, or both. To stage the disease more accurately and identify those patients for whom adjuvant therapy might be beneficial, detailed lymph node evaluation is prudent.

Sentinel lymph node (SLN) mapping seeks to identify the first lymph node to harbor metastatic disease from a nearby tumor and has become an integral part of patient selection for adjuvant treatment in solid malignancies such as breast cancer and melanoma. However, no reliable method is available for SLN evaluation in non-small cell lung cancer (NSCLC), mostly because of the physical properties of the lung and thoracic cavity. The ability to identify the lymph nodes at greatest risk of metastatic spread (ie, SLNs) to conduct more detailed histologic and molecular analysis would allow for better patient selection for adjuvant therapy in the hopes of improving survival and decreasing recurrence. To date, the use of radioisotopes or blue dye for lymphatic mapping has not been successfully translated to lung cancer secondary

to anthracotic nodes, poor intraoperative visibility, and procedural feasibility. In the present report, we review previous attempts at SLN identification in non-small-cell lung cancer and discuss our research using indocyanine green (ICG) dye and near-infrared (NIR) fluorescence imaging to identify the SLN in early-stage lung cancer.

HISTORY OF SLN MAPPING

Early Greek philosophy supported the hypothesis that cancer was a local manifestation of a systemic disease. However, early in the 19th century, Virchow implicated the lymph nodes in the process of the local spread of solid tumors to a more widespread systemic disease. This hypothesis led to the Halstedian model in breast cancer of en bloc dissection.² Numerous reports by Gould and colleagues,³ Cabanas,⁴ and Chiappa and colleagues⁵ individually identified lymphatic mapping in parotid, penile, and testicular cases, respectively; however, the term “sentinel” was finally coined by Weissbach and Boedefeld⁶ while examining the feasibility of limited retroperitoneal lymph node dissection. The concept of SLN biopsy, as we currently know it, was first made popular from studies by Morton and colleagues⁷ in 1989. Using blue dye, they performed a feasibility study in a feline model and translated this into clinical trials of patients with melanoma. Their results indicated that biopsy and analysis of SLNs accurately reflected the tumor status of the lymph node basin. Soon after, SLN biopsy was introduced for breast cancer patients.⁸ Additional studies have supported SLN biopsy as a method of identifying patients at greatest risk of locoregional recurrence and metastatic spread and, therefore, most likely to benefit from adjuvant therapy.

SLN MAPPING IN NON-SMALL CELL LUNG CANCER

SLN biopsy is currently the standard of care for patients with melanoma and breast cancer; however, these methods have not been successfully translated to non-small lung cancer. Understaging of early lung cancers could be secondary to inadequate node sampling because the hilar or

From the Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Mass.

Disclosures: Authors have nothing to disclose with regard to commercial support. Presented at the 3rd International Minimally Invasive Thoracic Surgery Summit, Boston, Massachusetts, October 7-8, 2011.

Received for publication Dec 16, 2011; revisions received April 6, 2012; accepted for publication May 18, 2012; available ahead of print June 22, 2012.

Address for reprints: Denis M. Gilmore, MD, Department of Thoracic Surgery, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115 (E-mail: dmgilmore@partners.org).

0022-5223/\$36.00

Copyright © 2012 by The American Association for Thoracic Surgery
<http://dx.doi.org/10.1016/j.jtcvs.2012.05.072>

Abbreviations and Acronyms

ICG	= indocyanine green
NIR	= near-infrared
NSCLC	= non-small cell lung cancer
SLN	= sentinel lymph node

mediastinal lymph nodes are not completely sampled at tumor resection in nearly 50% of patients.⁹⁻¹¹ In addition, the lymphatic drainage patterns in the lung are highly variable, making it difficult to predict the draining lymph node basin that should be sampled. An estimated 20% of SLNs have bypassed the nearby nodal basin (N1) and skipped to the mediastinal (N2) stations.¹² By removing only the nodes included with the resection specimen and failing to sample the hilar and mediastinal nodes, surgeons are missing these “skip” metastases. However, even if the SLN is removed at surgery, it is currently processed using conventional histological analysis that often fails to detect micrometastatic disease. This prospect is particularly worrisome, given that nearly 16% of patients with histologically node-negative lung cancer and up to 27.5% of patients with subcentimeter adenocarcinoma have evidence of micrometastatic disease or disseminated tumor cells within the sampled nodes when analyzed retrospectively with more time-intensive “SLN” histologic analysis techniques. Additional immunohistochemistry staining and polymerase chain reaction evaluation reserved for SLN analysis have been shown to increase the detection of occult micrometastasis in nodal disease. This is important because untreated occult micrometastatic disease has been shown to correlate with a threefold increase in recurrence and a significant decrease in patient survival.¹³ If pathologists knew which nodes to scrutinize (ie, the SLN), focused histologic and molecular examination could be performed of these nodes for evidence of micrometastasis. As such, intraoperative lymphatic mapping could help guide surgeons directly to the draining lymph nodes so they can be selected for additional in-depth analysis.

The conventional methods of SLN mapping have been attempted for NSCLC but have remained unreliable. The first attempt at SLN biopsy in lung cancer was performed using blue dye in 1999 by Little and colleagues.¹⁴ A total of 36 patients were studied, and only 47% of patients had a SLN identified. This was attributed to difficulties visualizing the dye in anthracotic nodes and poor technique. The investigators concluded that the rate of SLN identification was unacceptably low but equivalent to those from early melanoma and breast SLN trials. The investigators advocated for the addition of radiolabeled tracers to improve the sensitivity and specificity; however, this combination has also not proved successful.

Liptay and colleagues¹⁵ were the first group to report the use of an intraoperative radioactive tracer in lung cancer studies in 2000 (Table 1). Their technique of intraoperative injection of technetium-99m resulted in successful radioisotope migration in 81% of patients and SLN identification in almost 87%.¹⁵ Also, SLN analysis of previously deemed negative lymph nodes resulted in a diagnosis of occult micrometastatic disease in 24% of these patients. Furthermore, in just more than one third of the patients in whom a positive SLN was identified, the sentinel node was the only node with metastatic disease. In addition, 25 of the 104 SLNs had skipped directly to the mediastinum, highlighting the difficulty with SLN mapping in the lung. This initial phase I study with technetium-99m was encouraging and led to a phase II Cancer and Leukemia Group B multicenter trial focusing on intraoperative injection of technetium-99m in patients with suspected stage I NSCLC. However, the results from that study were discouraging, because patient accrual was less than 50%, and of those enrolled, only 51% of the SLNs were identified. The slow accrual was attributed to the logistic issues of organizing nuclear medicine, surgery, and pathology for intraoperative injection and analysis and the cumbersome regulations for radioactivity handling. Failure of SLN identification was attributed to the learning curve for the injection technique, the “shine through” effect in which the high radioactive signal from the tumor injection site produces false-positive results from increased background signal in nearby tissue, and background aerosolization of radioactivity.¹⁶ After that study, it was clear that additional measures were needed to successfully identify the SLN in the thorax.

Various techniques have been attempted to increase the sensitivity and specificity of SLN identification in lung cancer using radioisotopes. From the idea that lymphatic vessels might be disrupted during intraoperative incision and dissection, preoperative computed tomography-guided injection and intraoperative injection using a transbronchial approach were proposed. However, Japanese law states that radioisotopes can only be injected in dedicated rooms. Thus, preoperative injection of radioisotopes was normally performed 18 hours before surgery. SLN identification, however, remained low at only 81% of a total 104 patients in that study. Failure to reliably identify the SLN was again attributed to the “shine through” effect of radioactivity from the tumor into nearby tissues, making detection separate from the background difficult, residual radioactivity in the tracheobronchial tree, and possible decreased lymphatic density or impaired lymphatic flow in patients with a low forced expiratory volume in 1 second/forced vital capacity ratio.¹⁷ The technical complications associated with preoperative injection included bleeding, pneumothorax, and potential tumor seeding along the injection track. Again, locating the SLN in lung cancer in every patient remained an elusive goal.

TABLE 1. Initial sentinel lymph node biopsy mapping studies in non-small cell lung cancer

Group	Year	Technique	Success rate (%)
Little et al ¹⁴	1999	Blue dye	47
Liptay et al ¹⁵	2000	Radioisotope	81
Liptay et al ¹⁶	2009	Radioisotope	51
Noromi et al ¹⁷	2007	Preoperative radioisotope	81
Schmidt et al ¹⁸	2002	Intraoperative blue dye/radioisotope	81
Tiffet et al ¹⁹	2005	Intraoperative blue dye/radioisotope	54

Therefore, 2 separate groups used the strategy of combining both blue dye and radioisotopes to aid in the detection of the SLN in patients with lung cancer. Schmidt and colleagues¹⁸ used intraoperative injection of both blue dye and technetium-99m to identify the mediastinal lymph nodes. However, again, the rate of SLN identification was only 81%.¹⁸ The second group, Tiffet and colleagues,¹⁹ studied intraoperative injection of both markers, identifying SLN in only 13 (54%) of 24 patients, with some patients exhibiting only blue dye or technetium-99m migration and not both markers.¹⁹ These previous approaches have demonstrated the technical difficulty of visualizing blue dye within the anthracotic nodes and the differences in anatomy that make use of Geiger counters to identify radioisotopes difficult. In addition, the use of radioactivity poses a biologic risk to the surgeon, operating room personnel, patient, and pathologist and is limited by the “shine through” to nearby structures. As a standard approach to the thousands of patients with lung cancer, this is not an ideal solution. The poor reliability negates the clinical utility of these approaches and new innovations are needed.

NIR IMAGING

Recent success with ICG in lymph node mapping in pre-clinical trials involving animal models and clinical trials of breast cancer have renewed the interest in SLN biopsy in NSCLC.^{20,21} NIR fluorescence uses safe NIR excitation to provide simultaneous intraoperative imaging of visible reflected light and the NIR fluorescence emitted from ICG (Figure 1). ICG can quickly and reliably migrate to draining lymph node basins, permitting rapid and accurate SLN identification in a real-time intraoperative setting. Invisible NIR light penetrates into tissue, detecting fluorescent objects at a depth of 1 cm in solid tissue. By maintaining separation of the visible and NIR fluorescent light, it is possible to simultaneously acquire color and NIR fluorescence images and to overlay the 2 images. Thus, a single, intraoperative procedure is available to visualize SLNs, in which the surgical field remains unaltered, without additional radiation risk to the patient or operating staff. To date, NIR-guided SLN detection in nonthoracic systems has been characterized by the identification of the SLN using NIR technology and

FIGURE 1. Near-infrared imaging. The light source of normal white light and near-infrared fluorescence is reflected off the surgical field and collected by the camera, producing a real-time merged image.

concurrent real-time videoscopic images of the necessary anatomic landmarks required for safe and accurate surgical dissection, low background signal from biologic tissue, a nearly 100% sensitivity owing to the high signal/noise ratio in the node, and successful identification of a single SLN station in more than 90% of cases.

TECHNIQUE

In our phase I clinical trial, we assessed the safety and feasibility of NIR imaging using ICG for SLN identification in NSCLC in 29 patients. From the results of large animal studies, our initial technique consisted of peritumoral subpleural injection of low-dose ICG (3.8 μ g) coupled with fresh frozen plasma under direct visualization using the open-platform fluorescence-assisted resection and exploration camera. After injection, the surgeon proceeded with the planned operation, avoiding excision of the tumor or manipulation of the lymphatic drainage system while the ICG was migrating within the lymphatic channels to the SLN for at least 5 minutes and for up to 20 minutes. Inconsistent visualization of migration and/or SLN identification led to the following alterations of our initial technique.

Imaging Platform

At the onset of our trial, most lung resections were performed through a thoracotomy, making the open FLARE

FIGURE 2. A, After peritumoral injection of indocyanine green, near-infrared imaging can be used to identify sentinel lymph nodes intraoperatively. After dissection of the lymph node, ex vivo imaging confirms indocyanine green uptake in the lymph node in (B), merged near-infrared and visual light image, and (C) pure near-infrared image.

camera ideal for NIR imaging. As the standard of care shifted toward minimally invasive surgery, the imaging platform has also changed because we now use the 10-mm thoracoscope (Novadaq SpyScope, Richmond, British Columbia, Canada). Using both an open platform (FLARE, $n = 17$) and thoracoscopic (Novadaq SpyScope) NIR system ($n = 12$), we have been able to perform concurrent video and NIR imaging intraoperatively.

Coupling Agent

Adsorption of ICG to human serum albumin results in an increased hydrodynamic diameter and has the effect of increasing fluorescence, leading to improved SLN detection. Recent publications using ICG and NIR imaging for SLN mapping in breast cancer have used ICG coupled with albumin rather than fresh frozen plasma.²⁰ Owing to the potential risks of blood transfusion reactions and infection with fresh frozen plasma, we have changed our coupling agent to albumin without any difference in image quality resulting from the carrier protein.

Injection Depth

The lymphatic pathways of the lung are divided into superficial and deep vessels. The superficial system is the main system of lymphatic drainage and includes subpleural vessels and collecting systems that drain the segmental and lobar regions to the bronchopulmonary nodes. The deep system is composed of lymph capillaries draining the interlobular, perivascular, and peribronchial connective tissues to the bronchopulmonary lymph nodes but to a lesser degree.²²⁻²⁴ With this knowledge of the superficial lymphatic system, our initial technique consisted of shallow, subpleural injections. This technique often resulted in spillage of ICG from the injection site, with staining of the lung parenchyma and failure of lymphatic migration.

Similar issues were reported by others using NIR imaging for lung cancer, and a clip was placed at the injection site in an attempt to stop the leakage from the injection site.²⁵ We have found that one can usually circumvent this issue by injecting to depths of 1 cm with a fine gauge needle.

Lung Ventilation

Finally, we noted consistent visualization of the injection site but unreliable lymphatic migration when injected into deflated lung parenchyma. This difference was attributed to the decreased lymphatic flow in a nonventilated lung. Therefore, we transiently ventilated the lung. After injection of ICG, a short period of ventilation (<3 minutes) was performed, leading to improved consistency of lymphatic migration and SLN identification using NIR imaging (Figure 2).^{26,27}

These important technical details for successful NIR imaging in the lung have not previously been explored or reported in published studies. Our technique currently consists of intraparenchymal, peritumoral injection, followed by a short period of ventilation to improve lymphatic flow of ICG. Using a dose-escalation study, the best results have been obtained with the injection of 1 mL of 1 mg/mL ICG/albumin. As we move to phase II of the study, our goals are to confirm the reproducibility of these findings in a much larger group of patients; to determine whether the SLN identified using NIR imaging is currently being removed as a part of the conventional lymphadenectomy; and to assess whether focused SLN analysis can identify occult metastatic disease in patients identified as having “node-negative” disease using current non-SLN techniques.

CONCLUSIONS

Advances in lung cancer are needed to improve patient outcomes. The identification of the SLN and concomitant

focused in-depth histologic analysis of this node or nodes in search of occult micrometastatic disease could result in improved survival because selected patients could receive adjuvant therapy for previously undetected occult nodal disease. The current phase I trial has established the feasibility of SLN mapping in patients with lung cancer and has demonstrated that NIR mapping can be achieved in real time using a minimally invasive, intraoperative approach. Studies are underway to assess the optimal ICG dosing and the effect of SLN biopsy results on adjuvant therapy plans and overall outcomes in patients with early NSCLC staged using this technology.

References

- Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al, eds. *SEER Cancer Statistic Review, 1975-2008*. Bethesda, MD: National Cancer Institute; 2011. Available from http://seer.cancer.gov/csr/1975_2008.
- Halsted WS. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June 1889 to January 1894. *Johns Hopkins Hosp Bull*. 1894;4:297-323.
- Gould EA, Winship T, Philbin PH, Kerr HH. Observations on a "sentinel node" in cancer of the parotid. *Cancer*. 1960;13:77-8.
- Cabanas RM. An approach for the treatment of penile carcinoma. *Cancer*. 1977; 39:456-66.
- Chiappa S, Uslenghi C, Bonadonna G, Marano P, Ravasi G. Combined testicular and foot lymphangiography in testicular carcinomas. *Surg Gynecol Obstet*. 1966; 123:10-4.
- Weissbach L, Boedelfeld EA. Localization of solitary and multiple metastases in stage II nonseminomalous testis tumor as basis for a modified staging lymph node dissection in stage I. *J Urol*. 1987;138:77-82.
- Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. *Arch Surg*. 1992;127:392-9.
- Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. *Ann Surg*. 1994;220:391-8.
- Tsang GM, Watson DC. The practice of cardiothoracic surgeons in the perioperative staging of non-small cell lung cancer. *Thorax*. 1992;47:3-5.
- Little AG, Rusch VW, Bonner JA, Gaspar LE, Green MR, Webb WR, et al. Patterns of surgical care of lung cancer patients. *Ann Thorac Surg*. 2005;80: 2051-6.
- Verhagen AF, Schoenmakers MCJ, Barendregt W, Smit H, van Boven W-J, Looijen M, et al. Completeness of lung cancer surgery: is mediastinal dissection common practice? *Eur J Cardiothorac Surg*. 2012;41:834-8.
- Takizawa T, Terashima M, Koike T, Watanabe T, Kurita Y, Yokoyama A, et al. Lymph node metastasis in small peripheral adenocarcinoma of the lung. *Thorac Cardiovasc Surg*. 1998;116:276-80.
- Kubuschok B, Passlick B, Izbicki JR, Thetter O, Pantel K. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small cell lung cancer. *J Clin Oncol*. 1999;17:19-24.
- Little A, DeHoyos A, Kirgan DM, Arcomano TR, Murray KD. Intraoperative lymphatic mapping for non-small cell lung cancer: the sentinel node technique. *J Thorac Cardiovasc Surg*. 1999;117:220-4.
- Liptay MJ, Master GA, Winchester DJ, Edelman BL, Garrido BJ, Hirschtirt TR, et al. Intraoperative radioisotope sentinel lymph node mapping in non-small cell lung cancer. *Ann Thorac Surg*. 2000;70:384-9.
- Liptay MJ, D'Amico TA, Nwogu C, Demmy TL, Wang XF, Gu L, et al. Intraoperative sentinel node mapping with technetium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial. *J Thorac Oncol*. 2009;4:198-202.
- Noromi H. Sentinel lymph node mapping in lung cancer: the Japanese experience. *Semin Thorac Cardiovasc Surg*. 2009;21:316-22.
- Schmidt FE, Woltering EA, Webb WR, Garcia OM, Cohen JE, Rozans MH. Sentinel nodal assessment in patients with carcinoma of the lung. *Ann Thorac Surg*. 2002;74:870-5.
- Tiffet O, Nicholson AG, Khaddage A, Prevot N, Ladas G, Dubois F, et al. Feasibility of the detection of the sentinel lymph node in peripheral non-small cell lung cancer with radio isotopic and blue dye techniques. *Chest*. 2005;127: 443-8.
- Troyan SL, Kianzad V, Gibbs-Strauss SL, Gioux S, Matsui A, Oketokoun R, et al. The FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in breast cancer sentinel lymph node mapping. *Ann Surg Oncol*. 2009;16:2943-52.
- Khullar O, Frangioni JV, Grinstaff M, Colson YL. Image-guided sentinel lymph node mapping and nanotechnology-based nodal treatment in lung cancer using invisible near-infrared fluorescent light. *Semin Thorac Cardiovasc Surg*. 2009; 21:309-15.
- Nagaishi C. *Functional Anatomy and Histology of the Lung*. Tokyo, Japan: Igaku Shoin Ltd; 1972.
- Hayek H. *Die menschliche Lunge*. Berlin: Springer-Verlag; 1953.
- Topol MŁ, MasŁoń A. Some variations in lymphatic drainage of selected bronchopulmonary segments in human lungs. *Ann Anat Anat Anzeig*. 2009;191: 568-74.
- Yamashita S, Tokuishi K, Miyawaki M, Anami K, Moroga T, Takeno S, et al. Sentinel node navigation surgery by thoracoscopic fluorescence imaging system and molecular examination in non-small cell lung cancer. *Ann Surg Oncol*. 2012; 19:728-33.
- Albelda SM, Hansen-Flaschen JH, Lanken PN, Fishman AP. Effects of increased ventilation on lung lymph flow in unanesthetized sheep. *J Appl Physiol*. 1986;60: 2063-70.
- Ohnishi S, Lomnes SJ, Laurence RG, Gogbashian A, Mariani G, Frangioni JV. Organic alternatives to quantum dots for intraoperative near-infrared fluorescent sentinel lymph node mapping. *Mol Imag*. 2005;4:172-81.